CY1122229T1 - Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων - Google Patents

Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων

Info

Publication number
CY1122229T1
CY1122229T1 CY20191100352T CY191100352T CY1122229T1 CY 1122229 T1 CY1122229 T1 CY 1122229T1 CY 20191100352 T CY20191100352 T CY 20191100352T CY 191100352 T CY191100352 T CY 191100352T CY 1122229 T1 CY1122229 T1 CY 1122229T1
Authority
CY
Cyprus
Prior art keywords
materials
methods
treatment
hematologic malignancies
hematological malignancy
Prior art date
Application number
CY20191100352T
Other languages
English (en)
Inventor
Ayalew Tefferi
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of CY1122229T1 publication Critical patent/CY1122229T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Αυτό το έγγραφο παρέχει μεθόδους και υλικά που εμπλέκονται στην αντιμετώπιση αιματολογικών κακοηθειών. Για παράδειγμα, παρέχονται μέθοδοι και υλικά για τη χρήση αναστολέων τελομεράσης για την αντιμετώπιση αιματολογικών κακοηθειών όπως αιματολογικές κακοήθειες με γονότυπο μεταλλαγής στο σωμάτιο ματίσματος ή που παρουσιάζουν δακτυλιοειδείς σιδηροβλάστες εντός του μυελού των οστών. Ένας αναστολέας τελομεράσης όπως η Ιμετελστάτη ή Νατριούχος Ιμετελστάτη μπορεί να χρησιμοποιηθεί για την αντιμετώπιση αιματολογικών κακοηθειών με γονότυπο μεταλλαγής στο σωμάτιο ματίσματος ή που παρουσιάζουν δακτυλιοειδείς σιδηροβλάστες εντός του μυελού των οστών.
CY20191100352T 2013-11-06 2019-03-26 Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων CY1122229T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900854P 2013-11-06 2013-11-06
US201361904195P 2013-11-14 2013-11-14
PCT/US2014/064112 WO2015069758A1 (en) 2013-11-06 2014-11-05 Methods and materials for treating hematological malignancies

Publications (1)

Publication Number Publication Date
CY1122229T1 true CY1122229T1 (el) 2020-11-25

Family

ID=53042029

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100352T CY1122229T1 (el) 2013-11-06 2019-03-26 Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων

Country Status (16)

Country Link
US (1) US11123359B2 (el)
EP (2) EP3539547A1 (el)
JP (1) JP6532478B2 (el)
AU (1) AU2014346840B2 (el)
CA (1) CA2929809C (el)
CY (1) CY1122229T1 (el)
DK (1) DK3065828T3 (el)
ES (1) ES2717777T3 (el)
HR (1) HRP20190538T1 (el)
HU (1) HUE042792T2 (el)
LT (1) LT3065828T (el)
PL (1) PL3065828T3 (el)
PT (1) PT3065828T (el)
RS (1) RS58659B1 (el)
SI (1) SI3065828T1 (el)
WO (1) WO2015069758A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP7316261B2 (ja) * 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
CN112770783A (zh) 2018-07-31 2021-05-07 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
EP4182031A2 (en) * 2020-07-17 2023-05-24 Geron Corporation Subcutaneous telomerase inhibitor compositions and methods for using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201819789T4 (tr) * 2006-10-30 2019-01-21 Geron Corp Kanser tedavisine yönelik gemsitabin ve kombine telomeraz inhibitörü.
EP2534261B1 (en) 2010-02-12 2016-11-30 QIAGEN Marseille Asxl1 as a new diagnostic marker of myeloid neoplasms
CN110801454A (zh) 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
US9186295B2 (en) * 2011-10-25 2015-11-17 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2013151983A1 (en) * 2012-04-02 2013-10-10 The Cleveland Clinic Foundation Methods for predicting the prognosis of a subject with a myeloid malignancy
CA3188494A1 (en) * 2012-12-07 2014-06-12 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
CN112770783A (zh) 2018-07-31 2021-05-07 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法

Also Published As

Publication number Publication date
HRP20190538T1 (hr) 2019-05-17
RS58659B1 (sr) 2019-05-31
DK3065828T3 (en) 2019-04-15
CA2929809A1 (en) 2015-05-14
PT3065828T (pt) 2019-04-01
EP3065828B1 (en) 2019-01-09
US11123359B2 (en) 2021-09-21
CA2929809C (en) 2022-05-17
EP3539547A1 (en) 2019-09-18
EP3065828A4 (en) 2017-07-19
EP3065828A1 (en) 2016-09-14
HUE042792T2 (hu) 2019-07-29
AU2014346840A1 (en) 2016-06-02
AU2014346840B2 (en) 2020-02-06
PL3065828T3 (pl) 2019-06-28
SI3065828T1 (sl) 2019-04-30
JP6532478B2 (ja) 2019-06-19
ES2717777T3 (es) 2019-06-25
US20160287625A1 (en) 2016-10-06
JP2016537423A (ja) 2016-12-01
WO2015069758A1 (en) 2015-05-14
LT3065828T (lt) 2019-04-10

Similar Documents

Publication Publication Date Title
CY1124730T1 (el) Αντισωματα εναντι pd-1 και χρησεις αυτων
CY1122229T1 (el) Μεθοδοι και υλικα για την αντιμετωπιση αιματολογικων κακοηθειων
CL2017002401A1 (es) Anticuerpos contra icos
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1123957T1 (el) Θεραπεια συνδυασμου για καρκινο
CY1119510T1 (el) Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1124785T1 (el) Συνδυασμος ανταγωνιστη toy pd-1 και αναστολεα toy vegfr για την αντιμετωπιση του καρκινου
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1123067T1 (el) Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου
CY1125065T1 (el) Αναστολεις mcl-1
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
EA202091540A1 (ru) Антитела к lilrb2
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
EA201591137A1 (ru) Ингибиторы mk2 и их применения
CL2017002640A1 (es) Compuestos de pirazol y método para elaborar y usar los compuestos.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение